Skip to main content
Article thumbnail
Location of Repository

Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus

By R. Reeve, B. Blignaut, J.J. Esterhuysen, P. Opperman, L. Matthews, E.E. Fry, T.A.P. de Beer, J. Theron, E. Rieder, W. Vosloo, H.G. O'Neill, D.T. Haydon and F.F. Maree


Identifying when past exposure to an infectious disease will protect against newly emerging strains is central to understanding the spread and the severity of epidemics, but the prediction of viral cross-protection remains an important unsolved problem. For foot-and-mouth disease virus (FMDV) research in particular, improved methods for predicting this cross-protection are critical for predicting the severity of outbreaks within endemic settings where multiple serotypes and subtypes commonly co-circulate, as well as for deciding whether appropriate vaccine(s) exist and how much they could mitigate the effects of any outbreak. To identify antigenic relationships and their predictors, we used linear mixed effects models to account for variation in pairwise cross-neutralization titres using only viral sequences and structural data. We identified those substitutions in surface-exposed structural proteins that are correlates of loss of cross-reactivity. These allowed prediction of both the best vaccine match for any single virus and the breadth of coverage of new vaccine candidates from their capsid sequences as effectively as or better than serology. Sub-sequences chosen by the model-building process all contained sites that are known epitopes on other serotypes. Furthermore, for the SAT1 serotype, for which epitopes have never previously been identified, we provide strong evidence - by controlling for phylogenetic structure - for the presence of three epitopes across a panel of viruses and quantify the relative significance of some individual residues in determining cross-neutralization. Identifying and quantifying the importance of sites that predict viral strain cross-reactivity not just for single viruses but across entire serotypes can help in the design of vaccines with better targeting and broader coverage. These techniques can be generalized to any infectious agents where cross-reactivity assays have been carried out. As the parameterization uses pre-existing datasets, this approach quickly and cheaply increases both our understanding of antigenic relationships and our power to control disease

Publisher: Public Library of Science
Year: 2010
OAI identifier:
Provided by: Enlighten

Suggested articles


  1. (1993). A doi
  2. (1979). A Simple Sequentially Rejective Multiple Test Procedure. doi
  3. (2007). An evolutionary-network model reveals stratified interactions
  4. (1989). Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. doi
  5. (1995). Antibody recognition of picornaviruses and escape from neutralization: a structural view. doi
  6. (1990). Antigenic analysis of serotype O foot-and-mouth disease virus isolates from the Middle East, doi
  7. (1988). Antigenic sites on footand-mouth disease virus type A10.
  8. (1984). Antigenic variation in foot-and-mouth disease: studies based on the virus neutralization reaction. doi
  9. (2001). Bayesian selection of continuous-time Markov chain evolutionary models. doi
  10. (2008). Bioinformatics models for predicting antigenic variants of influenza A/H3N2 virus. doi
  11. (1993). Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus. doi
  12. (1999). Characterization of the structural-proteincoding region of SAT 2 type foot-and-mouth disease virus.
  13. (2010). Core Team doi
  14. (1998). Detection and characterization of foot-and-mouth disease virus in sub-Saharan Africa. doi
  15. (2006). Drummond A doi
  16. (1988). Evidence for more than one important, neutralizing site on foot-and-mouth disease virus. Brief report. doi
  17. (1984). Food and mouth disease virus strain differentiation: analysis of the serological data. doi
  18. (2001). Genetic heterogeneity of SAT-1 type foot-and-mouth disease viruses in southern Africa. doi
  19. (1992). Genetic relationships between southern African SAT-2 isolates of foot-and-mouth-disease virus. doi
  20. (1995). Genome variation in the SAT types of foot-and-mouth disease viruses prevalent doi
  21. (1989). Host cell selection of antigenic variants of foot-and-mouth disease virus. doi
  22. (1991). Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.
  23. (2006). Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. doi
  24. (2008). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Section 2.1.5. Foot and mouth disease: Version adopted by the World Assembly
  25. (2004). Mapping the antigenic and genetic evolution of influenza virus.
  26. (1978). Microneutralization tests for serological typing and subtyping of foot-and-mouth disease virus strains. doi
  27. (2003). Molecular epidemiology of SAT3-type foot-and-mouth disease.
  28. (1989). Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. doi
  29. (1996). Persistent infection of African buffalo (Syncerus caffer) with SAT-type foot-and-mouth disease viruses: rate of fixation of mutations, antigenic change and interspecies transmission. doi
  30. (1985). Phylogenies and the Comparative Method. Am Nat 125: 1–15. Antigenic Variability doi
  31. (2004). Predicting antigenic variants of influenza A/H3N2 viruses. doi
  32. (2007). Rambaut A doi
  33. (1990). Rapid and simple method for purification of nucleic acids.
  34. (1982). Rapid Evolution of RNA genomes. doi
  35. (1982). Rapid Evolution of RNA genomes. Science 215: 1577–1585. 2 .M a t t i o nN ,K o n i gG ,S e k iC ,S m i t s a a r tE ,M a r a d e iE ,e ta l doi
  36. (2004). Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease. doi
  37. (2003). Samuel A doi
  38. (2005). Selection of foot and mouth disease vaccine strains - a review.
  39. (1990). Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. doi
  40. (2009). Some guidelines for determining foot-and-mouth disease vaccine strain matching by serology. doi
  41. (1970). Statistical Methods for Research Workers, 14th Edition.
  42. (1987). Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination.
  43. (1934). The analysis of multiple classifications with unequal numbers in the different classes. doi
  44. (2003). The implications of virus diversity within the SAT 2 serotype for control of foot-andmouth disease in sub-Saharan Africa. doi
  45. (1994). The structure and antigenicity of a type C foot-and-mouth disease virus. doi
  46. (2001). The suitability of the ‘emergency’ footand-mouth disease antigens held by the International Vaccine Bank within a global context. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.